sponsored
PatientsVille.com Logo

PatientsVille

Leustatine Medical Research Studies

Up-to-date List of Leustatine Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Leustatine Medical Research Studies

Rank Status Study
1 Recruiting 2CDA With Rituximab in Hairy Cell Leukemia
Condition: Leukemia
Interventions: Drug: Cladribine;   Drug: Rituximab
Outcome Measure: Complete Response
2 Recruiting Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Condition: Leukemia
Interventions: Drug: Cladribine;   Drug: Cytarabine;   Drug: Decitabine
Outcome Measure: Disease-Free Survival (DFS)
3 Recruiting Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML)
Condition: Leukemia
Interventions: Drug: Cladribine;   Drug: Cytarabine;   Drug: Idarubicin;   Behavioral: Phone Calls
Outcome Measures: Complete Response Rate (CR);   Overall Response Rate (ORR)
4 Recruiting Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Interventions: Drug: Cladribine;   Drug: Rituximab
Outcome Measures: To determine if hairy cell leukemia (HCL) minimal residual disease (MRD) differs at 6 months after cladribine with or without rituximab administered concurrently with cladribine.;   To compare cladribine plus rituximab vs. cladribine alone in terms of 1) initial MRD-free survival and disease-free survival, and 2) response to delayed rituximab for relapse, to determine if early rituximab compromises later response.
5 Recruiting Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Untreated Adult Acute Myeloid Leukemia
Interventions: Biological: filgrastim;   Drug: mitoxantrone hydrochloride;   Drug: cladribine;   Drug: cytarabine
Outcome Measures: MTD of mitoxantrone hydrochloride, defined as the highest dose studied in which the incidence of dose-limiting toxicity is < 33%, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Phase I);   Minimal residual disease negative CR rate in patients with newly diagnosed disease (Phase II);   Remission rate (CR and CRp) of this regimen in patients with relapsed/refractory disease (Phase II)
6 Recruiting 4-Arm Phase II Study of SGI-110 in Elderly Acute Myeloid Leukemia (AML)
Condition: Leukemia
Interventions: Drug: SGI-110;   Drug: Idarubicin;   Drug: Cladribine
Outcome Measures: Complete Remission (CR) Rate;   Toxicity of 4 Different SGI-110 Single Agent and SGI-110 Based Combination Regimens.and SGI-110 Based Combination Regimens
7 Recruiting Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)
Condition: Mantle Cell Lymphoma
Interventions: Drug: Rituximab;   Drug: bortezomib;   Drug: Cladribine
Outcome Measures: Primary Outcome Dose Limiting Tolerability;   Secondary Outcome objective response rates
8 Recruiting R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukaemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Rituximab;   Drug: Cladribine
Outcome Measures: Response to treatment;   Duration of response
9 Recruiting Therapy Optimisation for the Treatment of Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Intervention: Drug: Cladribine s.c. injection, HCL treatment
Outcome Measures: Determination of the rate of complete remissions after one cycle with subcutaneous cladribine;   Rate of complete remissions in patient who still have detectable residual disease
10 Recruiting Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
Condition: Multiple Sclerosis
Intervention: Drug: Cladribine
Outcome Measures: Number of subjects with serious adverse drug reactions (SADRs);   Time to resolution of lymphopenia, among registry participants with persistent lymphopenia;   Number of subjects with all Adverse Events (AEs) in the "Blood and Lymphatic System Disorders" System Organ Class (SOC) and in the "Neoplasms Benign, Malignant, and Unspecified" SOC;   Pregnancy outcomes
11 Recruiting Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma
Conditions: Lymphoma;   Mantle Cell Lymphoma;   Indolent Lymphoma;   SLL
Interventions: Drug: rituximab;   Drug: bortezomib;   Drug: cladribine
Outcome Measures: Progression-free survival at 2 years;   Overall survival at 2 years;   Complete response and overall response rate;   Long- and short-term toxicity;   Cytokine profiles;   Prognostic importance of Aurora kinase A;   Prognostic importance of major carcinogenic pathways
12 Unknown  Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)
Condition: Leukemia, Myelocytic, Acute
Intervention: Drug: cladribine
Outcome Measures: Toxicity according to National Cancer Institute/Common Toxicity Criteria (NCI/CTC), especially the rate of severe infections and the death rate;   Rate of complete remission;   Remission duration;   Overall survival;   Influence of cytogenetic aberrations on remission rate, duration of remission and overall survival;   Course of CD3/CD4+ subpopulation after therapy
13 Recruiting Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Pulmonary Langerhans Cell Histiocytosis
Condition: Langerhans Cell Histiocytosis of Lung
Intervention: Drug: Cladribine
Outcome Measures: Cumulated incidence of response to treatment;   Responses to treatment;   Absolute variations of FEV1, FVC, residual volume (RV), and Diffusing capacity of the lung for carbon monoxide (DLCO), (expressed in mL);   Grade 3 or 4 neutropenia or thrombopenia;   Incidence of infection;   Incidence of grade 3 or 4 side effects;   Response to treatment of extra pulmonary localizations of the Langerhans disease;   Incidence of pneumothorax;   Mortality;   Incidence of secondary malignant disease;   Treatment response;   Variation of nodular and cystic semiquantitative scores in High Resolution Computed Tomography (HRCT)
14 Unknown  Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis
Condition: Advanced Systemic Mastocytosis
Intervention: Drug: Cladribine and pegylated interpheron alpha-2a
Outcome Measures: To evaluate the effect of therapy on bone marrow mast cell infiltration.;   To determine the effect of therapy on serum tryptase levels and other altered peripheral blood parameters due to mastocytosis.;   To evaluate the effect of therapy on mast cell-mediator release symptoms: pruritus, flushing, gastrointestinal symptoms or anaphylaxis).;   To determine de safety of combined therapy with low doses of cladribine plus pegylated interpheron alpha-2a.;   To evaluate the effect of therapy on mastocytosis skin lesions.;   To evaluate the effect of therapy on mastocytosis-related organomegalies.;   To evaluate the effect of therapy on mastocytosis-related bone alterations.
15 Recruiting Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: DAC;   Drug: CLAG;   Drug: Consolidation, I HAM cycle;   Drug: II Consolidation HiDAraC;   Drug: Consolidation, III HiDAraC cycle
Outcome Measure: Complete remission after induction
16 Unknown  Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia
Conditions: Acute Lymphoblastic Leukemia;   Lymphoblastic Lymphoma;   Burkitts Leukemia/Lymphoma;   Chronic Myelogenous Leukemia
Intervention: Drug: CLAG-M
Outcome Measures: Complete remission percentage;   Survival
17 Unknown  Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL)
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: valproic acid and 2-chlorodeoxyadenosine
Outcome Measures: To determine the tolerability of VPA in combination with low dose CdA in patients with advanced B-CLL;   minimal dose of VPA able to achieve adequate plasma levels of VPA and effective inhibition of VPA cellular targets, therapeutic response and survival , VPA pharmacokinetics
18 Recruiting Nonmyeloablative Allogeneic Transplant
Conditions: Aplastic Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Chronic Myelogenous Leukemia;   Chronic Lymphocytic Leukemia;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Mantle Cell Lymphoma;   Multiple Myeloma;   Waldenstrom Macroglobulinemia;   Breast Cancer;   Renal Cell Carcinoma;   Melanoma;   Sarcoma;   Ovarian Cancer;   Thymoma
Intervention: Procedure: Nonmyeloablative Allogeneic Transplant
Outcome Measures: Engraftment;   Graft-versus-host disease
19 Unknown  German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
Condition: Adult Acute Lymphocytic Leukemia
Interventions: Drug: Cyclophosphamide;   Drug: Dexamethasone;   Drug: Vincristine;   Drug: daunorubicin;   Drug: Asparaginase;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Mercaptopurine;   Drug: G-CSF;   Drug: Vindesine;   Drug: VP16;   Drug: Prednisolone;   Drug: Adriamycin;   Drug: Thioguanine;   Drug: VM26;   Procedure: CNS irradiation;   Procedure: Mediastinal Irradiation;   Procedure: Stem cell transplantation;   Drug: Idarubicin;   Drug: Fludarabine;   Drug: Cladribine
Outcome Measures: Remission rate, Remission duration, Disease free survival,Overall survival;   Time and dose compliance, Realisation of SCT, Toxicity according to WHO, Course of MRD
20 Recruiting Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
Condition: HIV
Interventions: Behavioral: Suubi+Adherence;   Behavioral: Bolstered Standard of Care
Outcome Measures: Change from baseline to follow-up assessments of adherence to HIV treatment;   Protective Health Behaviors;   Cost-Effectiveness Analyses

These studies may lead to new treatments and are adding insight into Leustatine etiology and treatment.

A major focus of Leustatine research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Leustatine